Ginkgo Bioworks, a cell programming and biosecurity platform, has announced that it has regained compliance with the NYSE minimum bid price requirement since its Class A common stock had a closing bid price at or above USD 1.00 on the last day of August and the company's 30-day trading average closed above USD 1.00.
Previously, on May 7, 2024, Gingko received a Continued Listing Standard Notice from the NYSE after it failed to comply with the NYSE’s minimum requirement on the average closing price of its Class A common stock.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.